507 related articles for article (PubMed ID: 35022014)
1. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
2. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
5. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Aboujaoude E; Barry JJ; Gamel N
J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
7. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
8. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
[TBL] [Abstract][Full Text] [Related]
9. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M; Ghorbanzadeh H; Moghaddam HS; Shalbafan M; Boroon M; Keshavarz-Akhlaghi AA; Akhondzadeh S
Psychiatry Clin Neurosci; 2023 Sep; 77(9):478-485. PubMed ID: 37169515
[TBL] [Abstract][Full Text] [Related]
10. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
[TBL] [Abstract][Full Text] [Related]
12. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Modarresi A; Sayyah M; Razooghi S; Eslami K; Javadi M; Kouti L
Pharmacopsychiatry; 2018 Nov; 51(6):263-269. PubMed ID: 29100251
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
14. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
16. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
[TBL] [Abstract][Full Text] [Related]
17. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial.
Tilaki EH; Hasanzadeh A; Shalbafan M; Moghaddam HS; Shamabadi A; Boroon M; Akhondzadeh S
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):175-180. PubMed ID: 37747999
[TBL] [Abstract][Full Text] [Related]
18. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
[TBL] [Abstract][Full Text] [Related]
20. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
